Shufen Xu

Jul 18, 2024 | onlinelibrary.wiley.com | Shufen Xu |Leslie Dan Faculty |Yue Xu |Nicholas C. Solek

Bowen Li Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, M5S 3M2 Canada Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, M5G 2C1 CanadaSearch for more papers by this author

Apr 24, 2024 | onlinelibrary.wiley.com | Shufen Xu |Leslie Dan Faculty |Yue Xu |Nicholas C. Solek

The advancement of mRNA-based immunotherapies for cancer is highly dependent on the effective delivery of RNA payloads using ionizable lipid nanoparticles (LNPs). However, the clinical application of these therapies is hindered by variable mRNA expression among different cancer types and the risk of systemic toxicity. The transient expression profile of mRNA further complicates this issue, necessitating frequent dosing and thus increasing the potential for adverse effects.